The Role of Cytokines and Adhesion Molecules for Mobilization of Peripheral Blood Stem Cells

Kronenwett, Ralf; Martin, Sylvia; Haas, Rainer

doi:10.1634/stemcells.18-5-320

Cited by 85 publications

(70 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD34, a cell-surface sialomucin commonly used for HSC purification, is suggested to play a role in cellular trafficking and migration (Kronenwett et al, 2000). However, CD34 may not be essential for the physiology of HSCs because normal hematopoietic profiles were found in CD34-null mice (Cheng et al, 1996;Guo et al, 2003).…”

Section: Discussionmentioning

confidence: 99%

“…CD34 + HSCs maintain a lifelong supply of multilineage hematopoietic cells that can be reconstituted in the blood as needed. During steady-state hematopoiesis, CD34 + HSCs circulate at low numbers in the peripheral blood, suggesting continuous migration of these cells between the bone marrow and organs (Kronenwett et al, 2000). Despite the wellrecognized molecular phenotype of CD34 + HSCs, the regulatory mechanisms for proliferation and the molecular signals mediating mobilization, migration, and differentiation are only partially understood (Awong et al, 2009;Han et al, 2003;Nielsen and MaNagny, 2009;Steidl et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification and Functional Characterization of Ion Channels in CD34+ Hematopoietic Stem Cells from Human Peripheral Blood

Park

Pang

Park

et al. 2011

Molecules and Cells

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Identification and Functional Characterization of Ion Channels in CD34+ Hematopoietic Stem Cells from Human Peripheral Blood

Park

Pang

Park

et al. 2011

Molecules and Cells

View full text Add to dashboard Cite

“…[23][24][25][26] Cytotoxic agents, with or without growth factor, are known to damage both hematopoietic and mesenchymal marrow stem cell compartments, thus suggesting that different chemotherapy agents might affect not only the quantity, but also the quality of mobilized progenitors. [27][28][29][30] No definitive assessment exists concerning the best chemotherapy mobilizing regimen given with G-CSF. 31,32 Hematological parameters including MNC or CD34 + cell pre-apheresis counts can probably predict hematopoietic stem cell collection.…”

Section: Discussionmentioning

confidence: 99%

Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma

Pavone

Gaudio

Guarini

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Our study analyzes the mobilization of hematopoietic stem cells after two chemotherapeutic regimens in nonHodgkin's lymphoma (NHL) patients. The study included 72 patients with NHL (42 follicular and 30 large cells). The mean age was 37 years (range 17-60). Sixty-four patients (88.9%) had stage III-IV disease. Forty-eight patients (66.7%) had bone marrow involvement. Systemic B symptoms were present in 42 patients (58.3%). Mobilization chemotherapy regimens were randomly assigned as DHAP in 38 patients (52.7%) or cyclophosphamide (CPM) (5 g/m 2 ) in 34 (47.2%) and the results of 132 procedures were analyzed. At the time of PBSC mobilization, 46 patients (63.9%) were considered to be responsive (complete remission, partial remission or sensitive relapse) and 26 (36.1%) not responsive (refractory relapse or refractory to therapy). Pre-apheresis CD34 + blood cell count and number of previous chemotherapy treatments were used to predict the total number of CD34 + cells in the apheresis product. The mobilizing regimens (CPM or DHAP) were similar in achieving the threshold CD34 + cell yield, for optimal engraftment. Since DHAP was very effective as salvage treatment, we suggest using DHAP as a mobilizing regimen in patients with active residual lymphoma at the time of stem cell collection. ( toxicity. [5][6][7][8] In the literature, high-dose cyclophosphamide (CPM) seems to be the gold standard for mobilizing hematopoietic progenitor cells in lymphoproliferative disorders. 9,10 Single high doses of alkylating agents (high-dose CPM or melphalan) have been used as mobilizing chemotherapy in NHL and other malignancies. [9][10][11][12] Combination chemotherapy regimens such as DHAP or MAD or ESHAP have also been used for stem cell harvesting. [13][14][15] In a previous study the DHAP protocol has already shown real efficacy in debulking and in vivo purging in refractory or in partial remission NHL. 16,17 The DHAP regimen was thus integrated into various treatment plans tailored for NHL patients as a second-line therapy and salvage chemotherapy for PR patients, or as an intensification and mobilizing regimen in CR high risk patients. 16,17 In our previous experience, we used the DHAP protocol as salvage treatment in patients in PR or with refractory NHL. Few randomised studies report a comparison of mobilizing capacity of two different chemotherapeutic regimens such as ESHAP or ifosfamide vs CPM in lymphoproliferative disorders. [18][19][20] In our study 72 NHL patients undergoing PBSC transplantation were prospectively randomized to mobilize PBSC with the DHAP regimen or with high-dose CPM in order to evaluate whether there were any differences in the number of mononuclear cells harvested (× 10 8 /kg), CD34 + cells (×10 6 /kg), colony-forming units granulocyte-macrophage (CFU-GM) (×10 4 /kg) obtained or engraftment speed. Bone Marrow Transplantation Patients and methodsThe following parameters were examined in the two different mobilized groups: (1) Clinical: (i) type of mobilizing regimen (DHAP (cisplatin 100 mg/...

show abstract

“…The egress of CD34 þ cells from the BM is likely caused by a loss of adhesiveness of stem cells to stromal elements. 2 The adhesiveness is facilitated by an interaction between stromal derived factor 1 (SDF-1) and CXCR4 present on CD34 þ cells. 3,4 It is suggested that in the murine system G-CSF reduces SDF-1 within the BM through degradation of the chemokine by proteolytic enzymes which are released by neutrophils during mobilization.…”

Section: Introductionmentioning

confidence: 99%

Low CXCR4 membrane expression on CD34+ cells characterizes cells mobilized to blood

Dłubek

Drabczak-Skrzypek

Lange

2005

Bone Marrow Transplant

View full text Add to dashboard Cite

In this work, association between the presence and membrane density of CXCR4 and the effectiveness of mobilization was studied. Ninety G-CSF mobilized PBPC and 28 native BM (nBM) preparations obtained from healthy individuals for transplantation and BM obtained after G-CSF mobilized PBPC collection in 10 donors were investigated. Positivity for CD34, HLA-DR and CXCR4 were analysed in the three colour fluorescence. The cellular profile of PBPC differed from nBM preparations with respect to lower: (i) proportion of CD34 þ cells (0.64%70.04 vs 0.9270.07) and CD34 þ CXCR4 þ cells (0.30%70.02 vs 0.6170.07); (ii) contribution of CXCR4 þ cells to CD34 þ cells (52.2%72.5 vs 62.2%74.2); (iii) CXCR4 epitope density in CD34 þ cells (48.975.5 vs 94.7710.4). PBPC yield for CD34 þ cells was correlated with the content of CD34 þ cells lacking CXCR4 in the leukapheresis product (R ¼ 0.38). In contrast, nBM harvested for transplantation was poor in CD34 þ cells if these cells were frequently CXCR4À (R ¼ À0.49). The present study shows that CD34 þ cells mobilized to blood were characterized with a low proportion of CXCR4 and this associated with CD34 þ cell content in PBPC.

show abstract

The Role of Cytokines and Adhesion Molecules for Mobilization of Peripheral Blood Stem Cells

Cited by 85 publications

References 105 publications

Identification and Functional Characterization of Ion Channels in CD34+ Hematopoietic Stem Cells from Human Peripheral Blood

Identification and Functional Characterization of Ion Channels in CD34+ Hematopoietic Stem Cells from Human Peripheral Blood

Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma

Low CXCR4 membrane expression on CD34+ cells characterizes cells mobilized to blood

Contact Info

Product

Resources

About